OpenAI's New AI Model Rosalind Could Shave Years Off Drug Discovery. You Probably Can't Use It
OpenAI's New AI Model Rosalind Could Shave Years Off Drug Discovery. You Probably Can't Use It Price data by News Artificial Intelligence OpenAI's New AI Model Rosalind Could Shave Years Off Drug Discovery. You Probably...
Bitcoin 1 Minute
Kripto piyasalarında dikkat çekici bir gelişme yaşandı. OpenAI's New AI Model Rosalind Could Shave Years Off Drug Discovery. You Probably Can't Use It Price data by News Artificial Intelligence OpenAI's New AI Model Rosalind Could Shave Years Off Drug Discovery. You Probably Can't Use It GPT-Rosalind is OpenAI's first domain-specific model, built for drug discovery and life sciences—and it's not for everyone.
By Jose Antonio Lanz Edited by Guillermo Jimenez Apr 18, 2026 Apr 18, 2026 4 min read OpenAI. Image: /Shutterstock Create an account to save your articles. Add on Google Add as your preferred source to see more of our stories on Google.
Piyasa Dinamikleri
In brief OpenAI unveiled GPT-Rosalind to accelerate drug discovery workflows. Benchmarks show strong gains, but real-world impact remains constrained . Access is tightly restricted amid rising biosecurity concerns.
OpenAI just named its first domain-specific AI model after Rosalind Franklin —the British chemist whose X-ray crystallography work helped reveal DNA's double helix, and who was famously denied credit for it during her lifetime. GPT-Rosalind, unveiled Thursday , is a purpose-built reasoning model for biology, drug discovery, and translational medicine. It's the first in what OpenAI is calling a Life Sciences model series—a direct play for a market where many specialized labs from universities to Google DeepMind are all jostling for position.
Getting a drug from target discovery to regulatory approval in the U. takes 10 to 15 years on average according to experts.. Most of that time disappears not in eureka moments, but in the grind: parsing thousands of papers, querying databases, designing reagents, and interpreting ambiguous results.
Piyasalara Etkisi
This is what GPT-Rosaling is trying to tackle. OpenAI argues the model can compress that early-stage work. As the company put it, GPT-Rosalind is designed to help scientists "explore more possibilities, surface connections that might otherwise be missed, and arrive at better hypotheses sooner.
" The benchmarks back up at least some of that ambition. On BixBench—a benchmark built around real-world bioinformatics tasks—GPT-Rosalind logged a 0. 751 pass rate, the top score among models with published results.
On LABBench2, it outperformed its predecessor GPT-5. 4 on six out of eleven tasks. GPT-Rosalind Beats GPT 5.
Blockchain ekosistemindeki bu gelişme, dijital varlık piyasalarını şekillendirmeye devam ediyor. Uzmanlar, konunun yakın vadeli etkilerini mercek altına alıyor.
